DRCR - Protocol AH

Pathology: Macular Hole

Description: Macular Hole Effects Pneumatic Vitreolysis on Macular Hole

Study Objectives: Primary - To compare the proportion of eyes with foveal VMT release on OCT after pneumatic vitreolysis with gas injection versus observation (sham injection) in eyes with VMT without an associated macular hole. Secondary - To evaluate visual function outcomes at 24 weeks after gas injection is performed compared with sham injection.

Principal Investigator: Dr. Blinder

Status: Enrollment - Currently Suspended


FOCUS - Novo Nordisk Trial

Pathology: Diabetic Retinopathy (DR)

Description: A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

Study Objectives: This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The study will be performed in people with type 2 diabetes. Participants will either get semaglutide or placebo in addition to their diabetes medicines - which treatment the participant gets is decided by chance. Participants will inject the study medicine using a pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. The study will last for 5 years.

Principal Investigator: Dr. Blinder (in connection with Dr. Fishman’s Office)

Status: Open Enrollment


GALLEGO

Pathology: Geographic Atrophy (GA)

Description: Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Study Objectives: This Phase 1, open-label, multicenter study will investigate the safety and tolerability of RO7171009 following single and multiple intravitreal (ITV) administrations in patients with GA secondary to AMD. The study consists of two stages: Single Dose-Escalation (SAD) and Multiple-Dose (MD) stages.

Principal Investigator: Dr. Blinder

Status: Open Enrollment